By Josh Beckerman
Shares of RenovoRx Inc. were higher for most of the trading day following news of favorable interim clinical trial data but declined after the company announced a registered direct offering.
The stock was recently down 21% to $3.10. RenovoRx said an institutional investor agreed to buy 1.56 million shares for $3.21 each. RenovoRx said it would issue 1.95 million warrants in a concurrent private placement.
RenovoRx said an interim analysis of a Phase III trial of RenovoGem therapy for pancreatic cancer patients shows a 6-month median overall survival benefit and fewer side effects than systemic chemotherapy.
Write to Josh Beckerman at [email protected]
Read the full article here